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Oxidative stressGenome-wide transcript proﬁling to elucidate responses to HSP90 inhibition revealed strong induc-
tion of HSPA6 in MCF-7 cells treated with 17-AAG. Time- and dose dependent induction of HSPA6
(conﬁrmed by qPCR and Western Blots) occurred also upon treatment with Radicicol, another
HSP90 inhibitor. HSPA6 was not detectable in untreated cells or cells treated with toxins that do
not inhibit HSP90, or upon applying oxidative stress. Thus, HSPA6 induction is not a general
response to cytotoxic insults. Modulation of HSPA6 levels by siRNA-mediated inhibition or recombi-
nant expression did not inﬂuence 17-AAG mediated cell death. HSPA6 induction as a consequence of
HSP90 inhibition occurs in various (but not all) cell lines and may be a more speciﬁc marker for
HSP90 inhibition than induction of other HSP70 proteins.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Geldanamycin is a small molecule that inhibits the function of
HSP90 family proteins [1,2]. As HSP90 is overexpressed in many
tumors, Geldanamycin is a candidate for anti-cancer therapies
[3], and efﬁcacy of Geldanamycin derivatives is evaluated in
numerous clinical trials [4–6]. Preliminary results suggest that
growth of HER2-positive breast cancers is particularly sensitive
towards HSP90 inhibition by the Geldanamycin derivative
17-AAG (Tanespimycin) [7]. This observation might be explained
by the dependency on HER2 expression of this cancer subset as
HER2 is a ‘‘client’’ protein of HSP90 [8]. HSP90 is a master regulator
of HER2 protein stability, and inhibition of HSP90 function results
in degradation of HER2 [8]. It appears, however, that some mem-
bers of the Heat shock 70 protein family become induced in
Geldanamycin treated cells which interferes with the therapeuticpotency of Geldanamycin [9]. In complete agreement with that, a
recent report demonstrates enhanced anti-cancer efﬁcacy upon
dual targeting of HSP90 and HSP70 in some cancer subtypes [10].
Therefore, a more detailed understanding of the interplay between
members of the cellular HSP network in the context of
HSP90-inhibition may improve anti-cancer therapies.
The HSP70 family comprises at least 13 members [11], of which
HSPA6 (HSP70B‘) appears evolutionary unique as it is not
conserved in rodents [12,13]. HSPA6 expression is not detectable
in most cells under normal conditions. It becomes induced upon
severe stress conditions and might mediate cytoprotective func-
tions in a cell-type and context-dependent manner [11,14,15].
The potential inﬂuence of drug-mediated HSP90 inhibition on
expression of HSPA6 has not been analyzed so far. This work
describes the speciﬁc induction of HSPA6 upon treatment of cancer
cells with HSP90 inhibitors.
2. Results
2.1. Geldanamycin induces the expression of HSPA6 in MCF-7 breast
cancer cells
A genome-wide analysis of transcriptional responses in MCF-7
breast cancer cells was performed upon exposure to respective
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to other cytotoxic compounds with cellular targets other than
HSP90: these included alpha-amanitin (ama, targets RNA-Pol),
saporin or cycloheximide (sap, CHX, both target the ribosome).
We were able to recapture previously described
Geldanamycin-mediated effects, such as the induction of various
HSP70 and HSP40 family members [16] (Table 1), thus validating
our experimental work-ﬂow. Surprisingly, we also observed that
HSPA6, a poorly characterized member of the HSP70 family
became induced to higher levels (more than 3000-fold) than any
other gene (up to 50-fold), even though induction of HSPA6 expres-
sion upon Geldanamycin treatment has not been described before.
HSPA7 is very closely related to HSPA6 (the putative HSPA7 protein
is 94% identical to HSPA6), but has been characterized as a pseudo-
gene [13,17]. Therefore, the mRNA hybridization signals could
have been derived from HSPA6 and/or HSPA7. To differentiate
between these two transcripts, we performed qPCR with three
different primer sets at different time points following 17-AAG
treatment. Each of these primer sets ampliﬁed regions of
HSPA6/HSPA7 with at least one nucleotide mismatch between
HSPA6 and HSPA7 sequences. We were subsequently able to dis-
tinguish between HSPA6/HSPA7 transcripts by sequencing tran-
script fragments derived from qPCRs at 4 h time point (=maximal
induction). This revealed that all ampliﬁed fragments exclusively
contained HSPA6 sequences, indicating exclusive (or at least pre-
dominant) induction of HSPA6 and not HSPA7 (Fig. 1). These
qPCR analyses also revealed that induction of HSPA6 transcripts
is time-dependent. It peaks around 4 h and declines to low levels
between 4 and 8 h after 17-AAG treatment (Fig. 1). Further,
HSPA6 mRNA induction is dose-dependent and saturation is
observed with concentration of 17-AAG between 125 and
250 nM (Fig. 1C). Next, we performedWestern Blot analyses to testTable 1
Induction of HSPA6 in 17-AAG treated MCF-7 cells. Cells were exposed for the indicated
(Sap = Saporin, CHX = Cycloheximide), protein (re-)folding (17-AAG = 17-N-allylamino-17
change values, i.e. fold changes are calculated according to the formula (Euler Constant)val
HSP70A, HSP70B, and HSP70L were detected with one speciﬁc probe for each mRNA and one
(positive values), decreased expression in red (negative values), minor or no changes in yif GA-induced HSPA6 transcription translates to HSPA6 protein
production. We separated 17-AAG treated and untreated MCF7 cell
extracts on SDS/PAGE followed by immunoblotting with a
HSPA6-speciﬁc antibody. HSPA6 protein is not detectable in
untreated, but in 17-AAG-treated cells (Fig. 2A). Similar to our
observations for HSPA6 mRNA levels, HSPA6 protein levels reach
a plateau at around 4 h following 17-AAG treatment (Fig. 2A) and
induction is concentration-dependent up to 500 nM 17-AAG
(Fig. 2B). In contrast to other HSP70 proteins (the
HSP70-antibody used in this study detects HSP72, HSPA1L as well
as HSPA8), which remain signiﬁcantly enriched even 24 h after
17-AAG treatment, HSPA6 protein levels decline rapidly between
the 8 h and 24 h time points (Fig. 2A).
Taken together, we conclude that exposure of MCF-7 cells to
17-AAG leads to a transient induction of HSPA6 protein expression.
2.2. HSPA6 expression is speciﬁcally induced by HSP90 inhibitors
A comparison of the genome wide mRNA proﬁles of MCF7 cells
treated with various toxins reveals that HSPA6 signals become
induced only by 17-AAG exposure, but not by toxins with targets
other than HSP90 (Table 1). This indicates that HSPA6 induction
is not a general response towards cytotoxic insults, but instead
either a speciﬁc consequence of treating cells with the substance
17-AAG, or triggered by inhibition of its molecular target HSP90.
In order to determine if induction of HSPA6 is a direct conse-
quence of HSP90-inhibition, we examined the effects of Radicicol,
another HSP90-inhibitor, on HSPA6 expression in MCF-7 cells.
Similar to 17-AAG, Radicicol induced HSPA6 mRNA (Fig. 3) in a
concentration-dependent manner. Maximum levels of induced
HSPA6 transcripts appear somewhat lower in Radicicol- compared
to 17-AAG-treated cells. This may be caused by the previouslytime periods to IC50 concentrations of toxins that either inhibit protein synthesis
-demethoxygeldanamycin), or transcription (Ama = alpha-amanitin). Listed are log
ue. Changes were observed with at least 2 probes for HSPA6/HSPA7, DNAJ and HSP90.
probe that detects HSP70A as well as HSP70B. Increased expression is indicated green
ellow.
A C
B
Fig. 1. Time- and dose-dependent induction of HSPA6, but not HSPA7, mRNA by 17-AAG. (A) MCF-7 cells were treated with 500 nM 17-AAG and mRNA extracted at different
time points, as indicated, after treatment. Following reverse transcription, qPCR assays were performed using 3 different primer sets for HSPA6/HSPA7. Ampliﬁcation of the
housekeeping gene GAPDH served as an internal control and reference. Values for HSPA6/HSPA7 represent fold-changes compared to expression in untreated cells. Statistical
analyses (one-way ANOVA, unpaired 2-tailed t-test) reveal signiﬁcant time-dependent differences of HSPA6 induction vs control with for all time points vs each other and
primer sets (P < 0.01 for all steps and primers except primer set 2 for 2–4 h P < 0.05). Induction levels decrease signiﬁcantly after 4 h (P < 0.01 4 h vs 8 h for all primer sets). (B)
PCR products derived from qPCR assays performed on samples from cells treated for 4 h with 17-AAG treatment (see (A)) were separated on a 2% Agarosegel, extracted,
column-puriﬁed and sequenced. Each primer set generated a single PCR-product of the expected size (224 bp for primer set1, 94 bp for primer set2, and 115 bp for primer
set3). Sequencing conﬁrmed the speciﬁc ampliﬁcation of HSPA6 as all sequences aligned to 100% with the reference sequence of HSPA6 and positions with mismatches
(marked ‘x’) for HSPA6 and HSPA7 did not amplify any signals, which could be derived from HSPA7 transcripts. The cDNA sources for HSPA6 were NCBI refseq NM_002155
and Genbank_AF093759 for HSPA7. The numbering of the HSPA6 and HSPA7 sequences relate to the nucleotide numbers in these sequences. (C) MCF-7 cells were treated for
4 h with different concentrations of 17-AAG, as indicated. QPCR assays were performed with HSPA6 primer set3 and GAPDH to determine fold-changes of HSPA6 transcripts
compared to untreated cells. Statistical analyses (one-way ANOVA, unpaired 2-tailed t-test) reveal signiﬁcant dose-dependent increases of HSPA6 induction vs control
(DMSO) with P < 0.03 for 62.5 nM, P < 0.02 for 62–125 nM. Induction reaches saturation after 125 nM (therefore induction levels do not increase further in a signiﬁcant
manner).
A B
Fig. 2. Time- and dose-dependent induction of HSPA6 protein by 17-AAG. (A) MCF-7 cells were treated with 500 nM 17-AAG and cells lysed at different time points, as
indicated, after treatment. Samples were separated on SDS–PAGE, proteins transferred to a PVDF membrane and HSPA6, HSP70 and Actin proteins detected with appropriate
antibodies. (B) MCF-7 cells were treated for 8 h with different concentrations of 17-AAG, as indicated, cells lysed and processed as described in (A).
1452 P. Kuballa et al. / FEBS Letters 589 (2015) 1450–1458described mRNA destabilization effects mediated by Radicicol
derivatives [18].
These results indicate that the speciﬁc trigger of HSPA6 induc-
tion is the inhibition of HSP90.
2.3. HSPA6 is not induced by Thapsigargin- or BrefeldinA-mediated
induction of the unfolded protein response
Cytotoxins, other than 17-AAG, used in our genome-wide tran-
scriptional analysis did not signiﬁcantly induce Heat shock 70 fam-
ily proteins (Table 1). Therefore, our data do not indicate if HSPA6represents a specialized, differentially regulated arm of the HSP70
family or if HSPA6 is commonly co-induced along with other
HSP70 proteins. 17-AAG has been reported to cause ER stress and
to induce genes of Unfolded Protein Response (UPR) pathway,
including the HSP70 family member GRP78/BiP (also known as
HSPA5 or HSP70-5) [19,20]. Further, GRP78/BiP is induced by other
ER stress/UPR inducing compoundswithmodes of action other than
HSP90 inhibition, e.g. Thapsigargin [21,22] and BrefeldinA [23,24].
Thus, we were wondering if treatment of cells with Thapsigargin
or BrefeldinA may also result in induction of HSPA6. Interestingly,
only 17-AAG and Radicicol, but not Thapsigargin or BrefeldinA
Fig. 3. Dose dependent induction of HSPA6 mRNA by Radicicol. MCF-7 cells were treated for 4 h with different concentrations of Radicicol, as indicated, or 1 lM of 17-AAG.
Subsequently, qPCR assays were performed as described in Fig. 1. Shown are fold-changes for HSPA6 compared to untreated cells. Statistical analyses (one-way ANOVA,
unpaired 2-tailed t-test) reveal signiﬁcant dose-dependent increases of HSPA6 induction vs lowest AAG concentration (12.3 nM) with P < 0.02 for 37 nM, P < 0.03 for 37–
111 nM, P = 0.054 for 333 nM and higher. Induction reaches saturation after 111 nM (therefore induction levels do not increase further in a signiﬁcant manner).
Fig. 4. HSPA6 induction is speciﬁcally triggered by HSP90 inhibition. MCF-7 cells
were treated for 6 h with approximately 4xIC50 concentrations of 17-AAG (1 lM),
Radicicol (1 lM), Thapsigargin (30 nM) or BrefeldinA (0.1 lg/ml). Following cell
lysis, samples were separated on SDS–PAGE, proteins transferred to a PVDF
membrane and HSPA6, GRP78/Bip, HSP70 and Actin detected with appropriate
antibodies.
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marker protein GRP78/BiP is strongly upregulated following treat-
ment with any of the 4 compounds tested (Fig. 4). This indicates- + - +- +- +- +- +
HSPA6
Acn
SK-BR3 MCF-7
- +
Raji
50
75
50
75
50
75
A
B C
Fig. 5. Induction of HSPA6 by 17-AAG in various cancer cell lines. (A–C) Cancer cell lines
and Table 2). HSPA6 and Actin protein levels were determined byWestern Blot analysis. (
determine if lack of HSPA6 induction is cell line or concentration dependent. (C) Raji and
to exclude detrimental effects on HSPA6 induction with very high concentrations of 17-that the trigger of HSPA6 induction is speciﬁcally and directly
linked to HSP90 inhibition, and not a consequence of UPR induction.
Also, expression of the HSP70 family proteins HSPA6 and GRP78/BiP
does not seem to be co-regulated. However, increased expression of
‘‘HSP70’’ (‘‘HSP70’’ = simultaneous detection of HSP72, HSPA1L and
HSPA8) is observed following treatment with 17-AAG and
Radicicol, but not Thapsigargin or BrefeldinA. Thus, induction of
HSPA6 expression correlates with upregulation of one or more
other HSP70 family proteins (Fig. 4 and Table 1). Like other HSP70
family members, HSPA6 becomes induced upon applying
heat-shock (Fig. 9 and Suppl. Fig. 5), most likely as consequence
of HSF-dependent transcription.
2.4. Induction of HSPA6 expression following HSP90 inhibition in
different cancer cell lines
Is HSPA6 induction upon HSP90 inhibition a speciﬁc feature
of MCF-7 (breast cancer) cells, or does it represent a more gen-
eral response that can be observed in other cells? To address this
question, we treated 12 different cancer cell lines with their
respective IC50 concentrations of 17-AAG (Fig. 5, Table 2 and
Suppl. Data S1) and determined HSPA6 levels by Western
Blotting. Of the 7 breast cancer cell lines that we analyzed, 4- + - + - + - +
HSPA6
Acn
HSPA6
Acn
- +
MCF-7
were treated for 6 h with their respective IC50 concentration of 17-AAG (see Fig. S1
B) In addition, 5xIC50 concentrations of 17-AAG have been applied to SK-BR3 cells to
MCF-7 cells have been treated with 20 lM 17-AAG (=estimated IC50 for Raji) for 6 h
AAG.
Fig. 6. ATP levels in MCF-7 cells following RNA Interference to blank HSPA6 induction in response to 17-AAG. MCF-7 cells were transfected with non-targeting (control) or
HSPA6-speciﬁc (#1–3) siRNA duplexes. (Upper panel), 4 h after transfection, cells were treated with 1 lM 17-AAG. 4 h after 17-AAG treatment cells were lysed, samples
separated on SDS–PAGE, and Actin and HSPA6 proteins detected by Western Blotting. (Lower panel), 4 h after transfection, cells were treated with increasing concentrations
of 17-AAG, as indicated. 72 h after 17-AAG treatment, Cell Titer Glo assays were performed.
Fig. 7. BrdU incorporation in MCF-7 cells following RNA Interference to blank HSPA6 induction in response to 17-AAG. MCF-7 cells were transfected with control siRNA (‘‘C’’)
or HSPA6-siRNA#3 (‘‘KD’’). (Upper panel), 4 h after transfection, cells were treated with increasing concentrations of 17-AAG, as indicated. 4 h after 17-AAG treatment cells
were lysed, samples separated on SDS–PAGE, and Actin and HSPA6 proteins detected by Western Blotting. (Lower panel), 4 h after transfection, cells were treated with
increasing concentrations of 17-AAG, as indicated. 24 h after 17-AAG treatment, BrdU incorporation assays were performed.
1454 P. Kuballa et al. / FEBS Letters 589 (2015) 1450–1458(MCF-7, KPL4, BT-474, MDA-MB-361) demonstrated a strong
induction of HSPA6 protein. The other three breast cancer cell
lines (MDA-MB-134-VI, MDA-MB-231, SK-BR3) showed no
induction of HSPA6 protein upon HSP90 inhibition (Fig. 5). Five
additional cell lines with tissue origins other than breast were
also examined. Among these, 17-AAG exposure does result in
strong HSPA6 induction in A-431 (epidermoid carcinoma) and
Colo-205 (colon cancer) cells, but not in Hep-G2 (liver cancer),
Molm-13 (Acute Myeloid Leukemia) and Raji (Burkitt’s
Lymphoma) cells (Fig. 5). Interestingly, the 3 cell linesMDA-MB-231, SK-BR3 and Raji cells which are rather unrespon-
sive to 17-AAG and require high concentrations of 17-AAG to
induce cell death do not induce HSPA6. Three of six cell lines
with medium sensitivity also lack HSPA6 induction. In contrast,
the three cell lines that are most sensitive to 17-AAG
(MDA-MB-361, Colo-205 and BT-474) are HSPA6 inducers
(Table 2 and Suppl. Fig. 2). However, lack of HSPA6 induction
may not reﬂect a general defect in mediating effects of HSP90
inhibition as induction of HSP70, but not HSPA6, is observed in
Raji cells (Suppl. Fig. 4).
B C
A
Fig. 8. ATP levels and BrdU incorporation in MCF-7 cells following HSPA6 overexpression and 17-AAG exposure. MCF-7 cells were transfected with pCMV6-entry (‘‘empty
vector’’) or pCMV6-HSPA6-untagged (‘‘HSPA6 vector’’) plasmids. 4 h after transfection medium was replaced. Another 20 h later, 17-AAG was added to increasing ﬁnal
concentrations, as indicated. (A), 4 h after 17-AAG exposure, cells were lysed, samples separated on SDS–PAGE, and Actin and HSPA6 proteins detected by Western Blotting.
(B), 72 h after 17-AAG treatment, Cell Titer Glo assays were performed. (C), 24 h after 17-AAG treatment, BrdU incorporation assays were performed.
Fig. 9. MDA-MB-231 or MCF-7 cells were treated for 6 h respective 4xIC50 concentration of various compounds, as indicated. HSPA6 and Actin protein levels were
determined by Western Blot analysis.
Table 2
IC50 concentrations of 17-AAG and HSPA6-responsiveness for all cell lines used in
this study. (⁄) Fold-induction of HSPA6 protein is estimated based on serial dilution of
HSPA6 signals in 17-AAG-treated Colo-205 cells (Suppl. Fig. 3).
Cell line Cancer IC50 (nM) HSPA6
induction (⁄)
MDA-MB-361 Breast 55 +(>8)
BT-474 Breast 100 +(>16)
Colo-205 Colon 125 +(>100)
KPL-4 Breast 250 +(>16)
MCF-7 Breast 250 +(>32)
MDA-MB-134-VI Breast 250 –
Molm-13 Acute Myeloid Leukemia 300 –
A-431 Epidermoid carcinoma 375 +(>4)
Hep-G2 Liver 375 –
MDA-MB-231 Breast 2000 –
SK-BR3 Breast 15000 –
Raji Burkitt’s lymphoma 20000 –
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AAG
The observation that the three cell lines that were least sensi-
tive to 17-AAG lacked HSPA6 induction and three cell lines that
were most sensitive to 17-AAG showed strong HSPA6 induction,
raises the question if HSPA6 levels directly affect the cytotoxicity
of 17-AAG. To this end, we transfected a scrambled siRNA or 3 dif-
ferent HSPA6-speciﬁc siRNAs into MCF-7 cells. All HSPA6-speciﬁc
siRNA sequences efﬁciently blocked induction of HSPA6 upon
treatment with 1 lM 17-AAG (Fig. 6, upper panel). Ablation with
HSPA6-siRNA#3 demonstrated an efﬁcient suppression of HSPA6
induction even at concentrations of 17-AAG up to 4 lM (Fig. 7).
Upon transfection of two siRNAs (HSPA6-siRNA#2 and 3) a modest
‘non-speciﬁc’ reduction of cell metabolism (ATP content, Fig. 6)
was observed in the absence of 17-AAG. However, HSPA6-siRNAs
did not affect cell proliferation rates (BrdU incorporation, Fig. 7).
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ing concentrations of 17-AAG revealed no difference in cellular
sensitivity between cells that induced HSPA6 and cells that did
not induce HSPA6 (Figs. 6 and 7). Next, we were wondering if
HSPA6 function might be relevant under conditions of very severe
stress. Therefore, we repeated our knock down experiments and
challenged cells by heat shock at 42 C with and without additional
17-AAG treatment. Heat shock and 17-AAG treatment alone or in
combination resulted in induction of HSPA6 protein, which could
be virtually blanked by our HSPA6-siRNA (Suppl. Fig. 5, upper
panel). Surprisingly, although HSPA6 induction seems to be very
strong upon heat stress in combination with 17-AAG challenge
(Suppl. Fig. 5, upper panel), ablation of HSPA6 does not affect cel-
lular sensitivity to both insults at any concentration of 17-AAG
(Suppl. Fig. 5, lower panel). Taken together, ablation of HSPA6
induction did not protect against 17-AAG or 17-AAG plus heat
shock mediated decline of cell proliferation or viability rates in
MCF-7 cells.
In addition, we also analyzed the effect of ectopic expression of
HSPA6 on 17-AAG sensitivity in MCF-7 cells. Transfections condi-
tions were optimized to generate steady-state levels of overex-
pressed HSPA6 comparable to 17-AAG-induced levels of
endogenous HSPA6 (Fig. 8, see Section 4 for transfection details).
Under the conditions used, ectopic expression of HSPA6 did not
alter cell proliferation and viability in the absence or presence of
17-AAG (Fig. 8). Further, MDA-MB-231 cells, which do not induce
endogenous HSPA6 in response to 17-AAG, do not show an altered
sensitivity towards 17-AAG when modiﬁed to stably overexpress
HSPA6 (Suppl. Fig. 6). Taken together, HSPA6 induction correlates
to some extent with 17-AAG responsiveness, but does not seem
to represent a survival factor or component that ameliorates
17-AAG toxicity.
2.6. MG132 and heat stress induce HSPA6 in cells that do not induce
HSPA6 in response to 17-AAG
HSPA6 induction following heat stress or treatment of cells with
the proteasome inhibitor MG132 have been described before. As
these triggers do not act via HSP90 inhibition, we were wondering
if these stimuli are effective for HSPA6 induction in cells that do
not induce HSPA6 in response to 17-AAG. MDA-MB-231 cells fail
to induce HSPA6 in response to 17-AAG, but show a prominent
induction of HSPA6 following treatment with 4xIC50 concentration
of MG132 (Suppl. Fig. 7) or exposure of cells to 42 C for 1 h or 2 h
(Fig. 9). In contrast, MCF-7 cells induce HSPA6 protein in response
to MG132, heat shock and 17-AAG (Fig. 9). This may suggest, that
transcriptional upregulation of HSPA6 in response to 17-AAG is not
solely dependent on the Heat Shock Element (HSE) within the
HSPA6 promoter region. In addition, we tested additional cytotoxic
compounds, that act in a HSP90-independent manner. No
induction of HSPA6 could be observed following exposure of
MCF-7 cells to respective 4xIC50 concentrations (Suppl. Fig. 7) of
the autophagosome-lysosome-fusion inhibitor BaﬁlomycinA1, the
lysosome inhibitor Hydroxychloroquine, the oxidative stress
inducer Hydrogenperoxide or the protein kinase inhibitor
Staurosporine (Fig. 9). This further supports the notion that
HSPA6 induction is not a general response to cytotoxic insults,
but rather controlled in a very deﬁned, yet complex, manner.3. Discussion
Geldanamycin derivatives, such as 17-AAG, are drug candidates
for anticancer therapy [4–6]. The target of Geldanamycin, HSP90, is
overexpressed in many cancer tissues studied to date [3]. However,
cancer cells seem to be able to escape cytotoxic effects of HSP90inhibition by a (possibly compensatory) upregulation of other heat
shock proteins, particularly members of the HSP70 family [9,10].
Thus, a detailed knowledge of the interplay between members of
the cellular HSP network in the context of HSP90-inhibition might
help in the design of strategies that avoid the activation of escape
mechanisms by cancer cells. We report that in various cancer cell
lines, expression of HSPA6 protein is induced following administra-
tion of 17-AAG. This effect appears to be a speciﬁc consequence of
HSP90 inhibition, as only HSP90 inhibitors (17-AAG and Radicicol),
but not other cytotoxic compounds with different mode of actions,
result in a similar induction of HSPA6. In MCF-7 cells and several
other cell lines, HSPA6 induction on mRNA and protein level is a
time- and concentration-dependent consequence of treatment
with 17-AAG or Radicicol. Some other cell lines, however, do not
elicit a ‘HSPA6 response’, suggesting that cell line dependent fac-
tors may be implicated in the transcriptional control of HSPA6
downstream of HSP90. The molecular pathways of HSPA6 tran-
scriptional control are only beginning to be elucidated and control
of HSPA6 transcription is still poorly understood. A recent report
suggests the existence of positive as well as negative regulatory
elements in the HSPA6 promoter [25]. It is possible that one or
more HSP90 client protein(s) might be involved in the
transcriptional regulation of HSPA6. Our data point towards a tran-
scriptional control of HSPA6 following HSP90 inhibition that is
different from the induction of HSPA6 in response to the protea-
some inhibitor MG132 or heat stress. While heat shock induction
of HSPA6 is mediated by the heat shock element (HSE), induction
of HSPA6 in response to MG132 is not deﬁned on a molecular level.
HSE mediated transcription cannot fully explain HSPA6 regulation,
because some cell lines are fully competent to induce HSPA6 dur-
ing heat stress, but do not induce HSPA6 upon HSP90 inactivation.
Recently a functional AP-1 site within the HSPA6 promoter region
was described and MG132 is known to induce transcriptional
activity from AP-1 promoter sequences [25]. Thus, HSP90 inhibi-
tion, proteasome inhibition and heat shock might mediate HSPA6
induction by distinct mechanisms, of which only signaling down-
stream of HSP90 appears to be highly cell type speciﬁc. It would
be of interest to determine if the postulated promoter elements
C/EBP or ZFX may be involved in HSPA6 induction downstream
of HSP90 [25].
It has been suggested that HSPA6 can form a complex with
HSP90, but no function has been assigned to this putative
HSPA6/HSP90 complex. Interestingly, formation of HSPA6/HSP90
complexes is Geldanamycin-dependent [26]. Given the absence
of HSPA6 expression in untreated cells, it is tempting to speculate
that Geldanamycin-dependency of this complex formation is sim-
ply reﬂected by Geldanamycin-dependent expression of HSPA6.
MG132, a proteasome inhibitor representing another class of
anti-cancer drugs also induces expression of HSPA6 in human cells
[27,28]. In this example, HSPA6 induction was suggested to be a
cellular ‘pro-survival’ response, because increased sensitivity
towards MG132-induced cell death has been reported for human
cell lines lacking a ‘HSPA6 response’ [27]. In contrast, our data indi-
cate that cell lines with high tolerance for 17-AAG (SK-BR3, Raji
and MDA-MB-231) do not induce HSPA6 expression (Fig. 5).
Furthermore, ablation of HSPA6 induction in 17-AAG sensitive
MCF-7 cells did not alter sensitivity towards 17-AAG-mediated cell
death (Figs. 6 and 7). A similar ﬁnding has been reported for heat
shock induced cell death, where neither knock down nor overex-
pression of HSPA6 did affect cell viability [11]. Thus, cell type
speciﬁc and context dependent factors might contribute to the
function and localization of HSPA6. Interestingly, localization to
the extracellular milieu [29], cell surface [28], centrioles [30] and
the nucleus [31], has been described for HSPA6.
Molecular markers to track HSP90 inhibition as well as more
detailed information about the consequences of HSP90 inhibition
P. Kuballa et al. / FEBS Letters 589 (2015) 1450–1458 1457are desired for basic research as well as in the clinic. HSPA6 mRNA
and protein are virtually undetectable in untreated cells, but highly
induced in 17-AAG treated cells (up to 7000-fold induction of
HSPA6 mRNA in MCF-7 cells, Fig. 1C). In contrast to general induc-
tion of HSP70 proteins (with background levels and general
UPR-induction (Fig. 2), determination of HSPA6 levels (mRNA or
protein) can represent a very clean and highly sensitive readout
for successful HSP90 inhibition. Especially at early time points
(2–8 h) following 17-AAG administration, fold-change is much
higher for HSPA6 as compared to other 17-AAG-responsive
genes/proteins, e.g. other HSP70 proteins (Table 1 and Fig. 2A).
A restriction in applying HSPA6 induction as general marker for
HSP90 inhibition is our observation that not all cell lines or cell
types induce HSPA6 following 17-AAG exposure. Thus, an initial
evaluation step of HSPA6-responsiveness in a given cell type/cell
line is required before applying HSPA6 as sensitive marker for
HSP90 inhibition.4. Materials and methods
4.1. Cell culture
MCF-7 [ATCC, HTB-22], KPL-4 [Kawasaki Medical School],
Hep-G2 [ATCC, HB-8065], Molm-13 [DSMZ, ACC-554], BT-474
[ATCC, HTB-20], A-431 [ATCC, CRL-1555], Colo-205 [ATCC,
CCL-222], MDA-MB-231 [ATCC, HTB-26], MDA-MB-361 [ATCC,
HTB-27], MDA-MB-134-VI [ATCC, HTB-23], Raji [ATCC, CCL-86]
and SK-BR3 [ATCC, HTB-30] cells were cultured at 37 C in 5%
CO2 atmosphere with 80% humidity. Following base media were
used: RPMI (MCF-7, Colo-205, BT-474, Molm-13, Raji), DMEM
(Hep-G2, A-431, KPL-4), L-15 (MDA-MB-134-VI, MDA-MB-231,
MDA-MB-361) and McCoy’s 5a (SK-BR3). Media contained
NaHCO3 at concentrations of 0.7 g/l (L-15 media), 2.0 g/l (RPMI
media) or 2.2 g/l (DMEM media). Further, all cell culture media
were supplemented with 10% fetal bovine serum and 2 mM
Glutamine. For culture of Molm-13 cells additional fetal bovine
serum was added (ﬁnal concentration = 20%) and culture media
for BT-474 cells was supplemented with human Insulin (ﬁnal
concentration = 10 lg/ml).
4.2. Affymetrix
Transcriptional proﬁling was performed by chip-based
(Affymetrix chip) hybridization analyses of mRNA isolated from
MCF-7 cells as previously described [32]. In brief, cells were seeded
and grown to subconﬂuency in 6-well plates and exposed to
17-AAG or other toxins, each at IC50 concentration. At different
time points thereafter, RNAs were prepared from these cells and
subjected to Affymetrix chip hybridization experiments according
to the manufacturer’s protocol. RNA from untreated MCF-7 cells
served as reference. All analyses were performed in triplicates,
and passed quality controls for mRNA/cDNA preparation.4.3. RT-PCR
For quantitative real time analysis of RNA transcripts, MCF-7
cells were seeded at 180000 cells per well on a 12-well plate.
The day after, test compounds were added to cells. At different
time points, as indicated, cells were lysed and RNA extracted
applying the RNeasy Mini kit (Qiagen). Following removal of geno-
mic DNA (TURBO DNA-free kit, Ambion), RNA was reverse tran-
scribed using a Transcriptor First Strand cDNA Synthesis Kit
(Roche). CDNA samples were mixed with SYBR Green Master Mix(Light Cycler RNA Master SYBR Green I kit), and speciﬁc ampliﬁca-
tion primers. QPCR was performed on a Lightcyler (Roche) applying
3 different primer pairs for HSPA6 [(HSPA6-Primer Set1, forward:
CAAGGTGCGCGTATGCTAC; reverse: GCTCATTGATGATCCGCA
ACAC), (HSPA6-Primer Set2, forward: CATCGCCTATGGGCTG GAC;
reverse: GGAGAGAACCGACACATCGAA), (HSPA6-Primer Set3, for-
ward: GATGTGTCGGTTCTCTCCATTG, reverse: CTTCCATGAAGT
GGTTCACGA)] and the primers GAPDHfor (GAAGGTGAAGGT
CGGAGTCA) and GAPDHrev (GAAGATGGTGATGGGATTTCCA) to
amplify the GAPDH housekeeping gene as normalization standard.
In subsequent experiments, HSPA6-Primer Set3 was used to quan-
tify HSPA6 transcripts.
4.4. Western Blotting, antibodies and recombinant proteins
For protein detection by Western Blotting, 600000 cells were
plated on 6-well plates. The day after, test compounds were added
to cells. At different time points, as indicated, cells were lysed in
RIPA buffer (Sigma) supplemented with complete protease inhibi-
tor cocktail (Roche). Cell lysates were normalized for total protein
amounts (BCA protein assay kit, Pierce) and resolved by SDS/PAGE
(4.12% NuPAGE SDS–PAGE, Life Technologies).
Following antibodies were used for immunodetection:
Anti-HSPA6 (OriGene Technologies, mouse monoclonal, clone
1D12), Anti-Beta-Actin (Sigma, mouse monoclonal, clone AC-74),
HSP70 (Cell Signaling), Anti-BiP (Cell Signaling, rabbit mAb, clone
C50B12), and HRP-coupled anti-mouse or anti-rabbit secondary
antibody (Dako, goat polyclonal). Recombinant HSPA1A and
HSPA8 used to determine speciﬁcity of HSPA6 and HSP70 antibod-
ies were purchased from origene (Catalog number TP10001 and
TP302209, respectively). For Western Blot analysis 500 ng of
recombinant protein was loaded per lane. The speciﬁcity of the
HSPA6 antibody was proven by several lines of evidence: knock-
down experiments applying HSPA6 mRNA speciﬁc reagents (gene
speciﬁc sequences) prevents generation of antibody-signals in
otherwise responsive cells, ‘17AAG unresponsive’ cell lines can
induce other HSP70 proteins upon 17AAG treatment but are still
negative for HSPA6 (crossreactivity of the HSPA6 antibody with
other HSPs would generate signals under such conditions), and
Western Blots with HSP70 proteins HSPA1A (Hsp70-1) and
HSPA8 (Hsc70) side by side with HSPA6 induced cell extracts
revealed no reactivity with both proteins.
4.5. RNAi and recombinant expression
For RNA Interference the following stealth siRNAs from
LifeTechnolgies were used: scrambled control siRNA (siRNA
Negative Control Med GC Duplex #2, catalog number
12935-112), HSPA6-siRNA#1 (HSS105080), HSPA6-siRNA#2
(HSS179391) and HSPA6-siRNA#3 (HSS179392). MCF-7 cells were
transfected with 30 pmol (60000 cells, 24 well format) or 5 pmol
(10000 cells, 96 well format) of respective siRNA duplexes with
Lipofectamine 2000 according to manufacturer’s manual. 4 h after
transfection cells were exposed to different concentrations of
17-AAG, as indicated. For overexpression experiments plasmids
encoding for no protein, herein referred to as ‘‘empty vector’’
(pCMV6-entry, origene, SKU RC207795) or HSPA6 without any tags
(HSPA6 (untagged), origene, SKU SC118784) were used. 400 ng
(60000 cells, 24well format) or 66,7 ng (10000 cells, 96 well for-
mat) total DNA were transfected with Lipofectamine 2000 accord-
ing to manufacturer´s manual. DNA mixes for HSPA6
overexpression contained 1/8 of HSPA6 vector and 7/8 of empty
vector. 4 h after transfection medium was replaced and another
20 h later 17-AAG was added.
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Cell numbers were detected based on total ATP levels (Cell Titer
Glo assay, Promega) and BrdU incorporation was used to quantify
cell proliferation rates (BrdU, ELISA etc. kit, Roche). Cell Titer Glo
and BrdU incorporation assays were performed 72 h and 24 h,
respectively, after exposure of cells to 17-AAG according to manu-
facturer´s instructions.
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